Companion Animal Infectious Disease Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Product, Infection Type, Technology, End-use, Animal Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Product Segment Analysis: Consumables, Reagents & Kits (Largest & Fastest-Growing Segment)

The consumables, reagents, and kits segment dominated the companion animal infectious disease diagnostics market, accounting for a 61.54% share in 2026, and is also expected to register the fastest growth, driven by the recurring demand for diagnostic materials in veterinary testing. These products are essential for identifying and monitoring infectious diseases in companion animals, including dogs, cats, and other household pets. The increasing prevalence of bacterial, viral, and parasitic infections, coupled with rising pet ownership and growing awareness of animal health, is strengthening demand for reliable and efficient diagnostic consumables. Reagents, assay kits, sample collection materials, and testing components are extensively used in veterinary laboratories, animal hospitals, diagnostic centers, and veterinary clinics to support routine screening, disease confirmation, and treatment monitoring. The recurring nature of diagnostic testing generates consistent demand for these products, while the growing adoption of rapid diagnostic kits and point-of-care testing is improving accessibility and turnaround times. Furthermore, advancements in assay sensitivity, test standardization, and user-friendly diagnostic formats are supporting broader adoption across veterinary care settings. Increasing emphasis on preventive veterinary healthcare, early disease detection, and timely treatment is further driving the use of consumables, reagents, and kits. The expansion of veterinary diagnostic infrastructure and the growing integration of advanced testing technologies are expected to sustain demand for these essential products as companion animal healthcare becomes increasingly focused on accurate, accessible, and efficient disease management.

Infection Type Segment Analysis: Bacterial (Largest Segment) vs Viral (Fastest-Growing Segment)

The bacterial infection segment accounted for a 42.78% share of the companion animal infectious disease diagnostics market in 2026, driven by the widespread occurrence of bacterial infections among companion animals and the growing need for timely diagnosis and effective treatment. Bacterial diseases can affect multiple organ systems in pets, contributing to respiratory, gastrointestinal, urinary tract, and skin-related conditions that require accurate identification and appropriate therapeutic management. The increasing awareness among pet owners regarding routine veterinary examinations, preventive healthcare, and early disease detection is supporting demand for bacterial infection diagnostics. Veterinary clinics and diagnostic laboratories are increasingly utilizing rapid diagnostic assays, bacterial culture methods, and antimicrobial susceptibility testing to identify infectious agents and guide treatment decisions. Growing concerns surrounding antimicrobial resistance are also encouraging more precise diagnostic practices to support responsible antibiotic use and reduce inappropriate treatment. In addition, improvements in diagnostic assay performance, sample processing, and laboratory testing workflows are enhancing the reliability and accessibility of bacterial infection detection. The continued expansion of veterinary healthcare services and the increasing emphasis on evidence-based treatment are expected to support sustained demand for bacterial infection diagnostics.

The viral infection segment is projected to experience the fastest growth, supported by increasing awareness of viral disease prevention, the need for rapid pathogen identification, and growing adoption of advanced veterinary diagnostic technologies. Viral infections can spread rapidly among companion animals and may cause significant health complications, making early detection and timely intervention essential for effective disease management. The growing focus on identifying contagious diseases, including respiratory and gastrointestinal viral infections, is encouraging veterinary professionals to adopt more sensitive and efficient diagnostic methods. Rapid antigen testing, molecular assays, and nucleic acid-based diagnostic techniques are improving the ability to detect viral pathogens, including during early stages of infection. Increasing investments in veterinary healthcare infrastructure, combined with rising demand for routine screening and preventive testing, are further supporting the adoption of viral diagnostics. In addition, greater awareness of vaccination programs, disease surveillance, and infection control is encouraging pet owners and veterinary professionals to prioritize timely viral disease testing. The growing availability of point-of-care diagnostic platforms is also enabling faster clinical decision-making in veterinary clinics and animal hospitals. Continued advancements in molecular detection, multiplex testing, and rapid diagnostic solutions are expected to expand the application of viral infection diagnostics across companion animal healthcare settings.

Technology Segment Analysis: Immunodiagnostics (Largest Segment) vs Molecular Diagnostic (Fastest-Growing Segment)

In 2026, the immunodiagnostics segment captured the largest market share in the companion animal infectious disease diagnostics market, supported by its widespread application in detecting infectious diseases through antigen-antibody interactions. Immunodiagnostic technologies, including enzyme-linked immunosorbent assays, lateral flow assays, and other antibody-based testing methods, are extensively used in veterinary clinics, diagnostic laboratories, and animal hospitals for routine disease screening and clinical assessment. Their relatively simple workflows, ease of use, rapid turnaround times, and compatibility with point-of-care testing make them suitable for veterinary settings with varying levels of diagnostic infrastructure. The growing emphasis on early disease detection, preventive veterinary care, and routine infectious disease screening is supporting the continued adoption of immunodiagnostic solutions. These technologies are particularly valuable for identifying specific pathogen antigens or antibodies, assisting veterinary professionals in evaluating infection status and supporting clinical decision-making. In addition, the availability of user-friendly testing formats and improvements in assay sensitivity and specificity are enhancing their suitability for decentralized veterinary diagnostics. Increasing pet ownership, expanding veterinary healthcare access, and rising awareness of companion animal wellness are further contributing to the adoption of immunodiagnostic technologies. Their established role in routine testing, combined with relatively accessible implementation and efficient sample processing, is expected to sustain their importance in companion animal infectious disease diagnostics.

The molecular diagnostic segment is projected to witness the fastest growth, driven by increasing demand for highly sensitive, specific, and accurate methods of detecting infectious pathogens in companion animals. Molecular diagnostic technologies, including polymerase chain reaction, real-time PCR, and other nucleic acid amplification techniques, enable the identification of pathogen-specific genetic material and support the detection of infections that may be difficult to diagnose using conventional methods. The growing need for early and reliable identification of bacterial and viral pathogens, particularly in cases involving complex or overlapping clinical symptoms, is accelerating the adoption of molecular diagnostic solutions. These technologies are increasingly being utilized in veterinary reference laboratories, specialized diagnostic centers, and advanced animal hospitals to improve diagnostic precision and support targeted treatment strategies. Growing concerns regarding emerging infectious diseases, zoonotic transmission, and antimicrobial resistance are further reinforcing the importance of molecular testing in veterinary healthcare. In addition, technological advancements in automated sample preparation, multiplex molecular assays, and portable diagnostic platforms are improving testing efficiency, accessibility, and workflow integration. The increasing availability of rapid molecular testing solutions is also supporting their adoption in decentralized veterinary settings, where timely diagnosis is essential for effective clinical management. As veterinary healthcare increasingly prioritizes precision diagnostics, early pathogen detection, and improved disease surveillance, molecular diagnostic technologies are expected to gain broader application across companion animal infectious disease testing.